TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Age-relatedMacularDegeneration (ARMD) Drugs Market Insights and Forecast to 2028

Global Age-relatedMacularDegeneration (ARMD) Drugs Market Insights and Forecast to 2028

  • Category:Life Sciences
  • Published on : 10 June 2022
  • Pages :109
  • Formats:
  • Report Code:SMR-7144840
OfferClick for best price

Best Price: $3920

AgerelatedMacularDegeneration ARMD Drugs Market Size, Share 2022


Market Analysis and Insights: Global AgerelatedMacularDegeneration ARMD Drugs Market

The global AgerelatedMacularDegeneration ARMD Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global AgerelatedMacularDegeneration ARMD Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global AgerelatedMacularDegeneration ARMD Drugs market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global AgerelatedMacularDegeneration ARMD Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global AgerelatedMacularDegeneration ARMD Drugs market.

Global AgerelatedMacularDegeneration ARMD Drugs Scope and Market Size

Age-relatedMacularDegeneration (ARMD) Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Age-relatedMacularDegeneration (ARMD) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Anti VEGF Drugs

Photosensitive Drugs

Others

Segment by Application

Exudative ARMD

Atrophy ARMD

By Company

Roche

Regeneron Pharmaceuticals

Bayer

Santen Oy

Kanghong Pharmaceuticals

Novartis

Eli Lilly and Company

TRACON Pharmaceuticals

Pfizer

GSK

BIOCAD

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes AgerelatedMacularDegeneration ARMD Drugs product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of AgerelatedMacularDegeneration ARMD Drugs, with price, sales, revenue, and global market share of AgerelatedMacularDegeneration ARMD Drugs from 2019 to 2022.

Chapter 3, the AgerelatedMacularDegeneration ARMD Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the AgerelatedMacularDegeneration ARMD Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the AgerelatedMacularDegeneration ARMD Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of AgerelatedMacularDegeneration ARMD Drugs.

Chapter 13, 14, and 15, to describe AgerelatedMacularDegeneration ARMD Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 AgerelatedMacularDegeneration ARMD Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Age-relatedMacularDegeneration (ARMD) Drugs Market Insights and Forecast to 2028
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 109 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Anti VEGF Drugs
1.2.3 Photosensitive Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Exudative ARMD
1.3.3 Atrophy ARMD
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Perspective (2017-2028)
2.2 Age-relatedMacularDegeneration (ARMD) Drugs Growth Trends by Region
2.2.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Region (2017-2022)
2.2.3 Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Region (2023-2028)
2.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Dynamics
2.3.1 Age-relatedMacularDegeneration (ARMD) Drugs Industry Trends
2.3.2 Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers
2.3.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges
2.3.4 Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Revenue
3.1.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Revenue (2017-2022)
3.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Age-relatedMacularDegeneration (ARMD) Drugs Revenue
3.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio
3.4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2021
3.5 Age-relatedMacularDegeneration (ARMD) Drugs Key Players Head office and Area Served
3.6 Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
3.7 Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Age-relatedMacularDegeneration (ARMD) Drugs Breakdown Data by Type
4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Type (2017-2022)
4.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Type (2023-2028)
5 Age-relatedMacularDegeneration (ARMD) Drugs Breakdown Data by Application
5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Application (2017-2022)
5.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2017-2028)
6.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
6.2.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
6.2.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028)
6.2.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2017-2028)
6.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
6.3.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
6.3.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028)
6.3.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2017-2028)
6.4 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
6.4.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022)
6.4.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2017-2028)
7.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
7.2.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
7.2.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028)
7.2.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2017-2028)
7.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
7.3.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
7.3.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028)
7.3.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2017-2028)
7.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
7.4.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022)
7.4.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2017-2028)
8.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
8.2.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
8.3.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region
8.4.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2017-2028)
9.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
9.2.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2017-2028)
9.3 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
9.3.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2017-2028)
9.4 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
9.4.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2017-2028)
10.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
10.2.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
10.3.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
10.4.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.1.4 Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.1.5 Roche Recent Developments
11.2 Regeneron Pharmaceuticals
11.2.1 Regeneron Pharmaceuticals Company Details
11.2.2 Regeneron Pharmaceuticals Business Overview
11.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.2.4 Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.2.5 Regeneron Pharmaceuticals Recent Developments
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.3.4 Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.3.5 Bayer Recent Developments
11.4 Santen Oy
11.4.1 Santen Oy Company Details
11.4.2 Santen Oy Business Overview
11.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.4.4 Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.4.5 Santen Oy Recent Developments
11.5 Kanghong Pharmaceuticals
11.5.1 Kanghong Pharmaceuticals Company Details
11.5.2 Kanghong Pharmaceuticals Business Overview
11.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.5.4 Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.5.5 Kanghong Pharmaceuticals Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.6.4 Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.6.5 Novartis Recent Developments
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Details
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.7.4 Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.7.5 Eli Lilly and Company Recent Developments
11.8 TRACON Pharmaceuticals
11.8.1 TRACON Pharmaceuticals Company Details
11.8.2 TRACON Pharmaceuticals Business Overview
11.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.8.4 TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.8.5 TRACON Pharmaceuticals Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.9.4 Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.9.5 Pfizer Recent Developments
11.10 GSK
11.10.1 GSK Company Details
11.10.2 GSK Business Overview
11.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.10.4 GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.10.5 GSK Recent Developments
11.11 BIOCAD
11.11.1 BIOCAD Company Details
11.11.2 BIOCAD Business Overview
11.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.11.4 BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
11.11.5 BIOCAD Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Anti VEGF Drugs
Table 3. Key Players of Photosensitive Drugs
Table 4. Key Players of Others
Table 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region (2017-2022)
Table 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region (2023-2028)
Table 11. Age-relatedMacularDegeneration (ARMD) Drugs Market Trends
Table 12. Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers
Table 13. Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges
Table 14. Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints
Table 15. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Players (2017-2022)
Table 17. Global Top Age-relatedMacularDegeneration (ARMD) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2021)
Table 18. Ranking of Global Top Age-relatedMacularDegeneration (ARMD) Drugs Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
Table 22. Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2017-2022)
Table 26. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2023-2028)
Table 28. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Application (2017-2022)
Table 30. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Application (2023-2028)
Table 32. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 62. Roche Company Details
Table 63. Roche Business Overview
Table 64. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 65. Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 66. Roche Recent Developments
Table 67. Regeneron Pharmaceuticals Company Details
Table 68. Regeneron Pharmaceuticals Business Overview
Table 69. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 70. Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 71. Regeneron Pharmaceuticals Recent Developments
Table 72. Bayer Company Details
Table 73. Bayer Business Overview
Table 74. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 75. Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 76. Bayer Recent Developments
Table 77. Santen Oy Company Details
Table 78. Santen Oy Business Overview
Table 79. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 80. Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 81. Santen Oy Recent Developments
Table 82. Kanghong Pharmaceuticals Company Details
Table 83. Kanghong Pharmaceuticals Business Overview
Table 84. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 85. Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 86. Kanghong Pharmaceuticals Recent Developments
Table 87. Novartis Company Details
Table 88. Novartis Business Overview
Table 89. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 90. Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 91. Novartis Recent Developments
Table 92. Eli Lilly and Company Company Details
Table 93. Eli Lilly and Company Business Overview
Table 94. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 95. Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 96. Eli Lilly and Company Recent Developments
Table 97. TRACON Pharmaceuticals Company Details
Table 98. TRACON Pharmaceuticals Business Overview
Table 99. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 100. TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 101. TRACON Pharmaceuticals Recent Developments
Table 102. Pfizer Company Details
Table 103. Pfizer Business Overview
Table 104. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 105. Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 106. Pfizer Recent Developments
Table 107. GSK Company Details
Table 108. GSK Business Overview
Table 109. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 110. GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 111. GSK Recent Developments
Table 112. BIOCAD Company Details
Table 113. BIOCAD Business Overview
Table 114. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 115. BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
Table 116. BIOCAD Recent Developments
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type: 2021 VS 2028
Figure 2. Anti VEGF Drugs Features
Figure 3. Photosensitive Drugs Features
Figure 4. Others Features
Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application: 2021 VS 2028
Figure 6. Exudative ARMD Case Studies
Figure 7. Atrophy ARMD Case Studies
Figure 8. Age-relatedMacularDegeneration (ARMD) Drugs Report Years Considered
Figure 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region: 2021 VS 2028
Figure 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Players in 2021
Figure 13. Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2021
Figure 15. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 16. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2028)
Figure 17. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2028)
Figure 18. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Country (2017-2028)
Figure 19. United States Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 22. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2028)
Figure 23. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2028)
Figure 24. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Country (2017-2028)
Figure 25. Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 32. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2028)
Figure 33. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2028)
Figure 34. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Region (2017-2028)
Figure 35. China Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 41. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 42. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2028)
Figure 43. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2028)
Figure 44. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Country (2017-2028)
Figure 45. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 48. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2028)
Figure 49. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2028)
Figure 50. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Country (2017-2028)
Figure 51. Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. UAE Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Roche Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 55. Regeneron Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 56. Bayer Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 57. Santen Oy Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 58. Kanghong Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 59. Novartis Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 60. Eli Lilly and Company Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 61. TRACON Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 62. Pfizer Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 63. GSK Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 64. BIOCAD Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount